A new Mobilise-D scoping review: The clinical utility of digital mobility outcomes

Walking has the potential to be a rich indicator of health in many medical conditions. In recent years, scientific research has proposed more than 100 digital mobility outcomes (DMOs) that could be used to assess walking, and thereby monitor health status, using digital technologies. Though they show great promise, these DMOs require further validation.  Researchers must…

Novartis job opportunity for analysis of wearable sensor data for Digital Mobility Outcomes

Novartis is now looking for a Digital Data Scientist to join their group and participate in their ground-breaking medical research activities that redefine the grammar for medicine in the post-genome era. The Digital Data Scientist in Novartis will understand complex and critical business problems, formulate integrated analytical approach to mine data sources, employ statistical methods…

Key challenges in the use & development of digital endpoints from a health technology assessment (HTA) perspective

Digital endpoints offer a great potential to be considered in the HTA framework. So far, however, there is no institutional way in.  On February 15, 2021, IMI Neuronet hosted an online meeting of its working group on health technology assessment (HTA) and regulatory interactions, moderated by Diana O’Rourke from the National Institute for Health and Care Excellence (NICE). The discussions were based around the experiences of three different IMI projects that are…

IMI article about our Digital Health Catalyst initiative

The Digital Health Catalyst (DHC) was created by Mobilise-D and IDEA-FAST in response to the growing need for research and application in the area of real-world digital measurements. “The field will require a new generation of personnel from areas including clinical research and application, sensor and hardware development, infrastructure and data handling, data processing and…

EMA Public Support for Mobilise-D

In the first year of Mobilise-D, we asked the European Medicines Agency (EMA) for qualification advice for Digital Mobility Outcomes (DMOs). EMA just published their letter of support that publicly endorses our initial stage in the wider objective of the Mobilise-D Consortium to pursue the qualification of Digital Mobility Outcomes (DMOs) as monitoring biomarkers of…